Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9

Glaucoma is a common cause of blindness, yet current therapeutic options are imperfect. Clinical trials have invariably shown that reduction in intraocular pressure (IOP) regardless of disease subtype prevents visual loss. Reducing ciliary body aqueous humor production can lower IOP, and the adeno-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiahui, Bell, Oliver H., Copland, David A., Young, Alison, Pooley, John R., Maswood, Ryea, Evans, Rachel S., Khaw, Peng Tee, Ali, Robin R., Dick, Andrew D., Chu, Colin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054720/
https://www.ncbi.nlm.nih.gov/pubmed/31981492
http://dx.doi.org/10.1016/j.ymthe.2019.12.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054720/
https://www.ncbi.nlm.nih.gov/pubmed/31981492
http://dx.doi.org/10.1016/j.ymthe.2019.12.012

Ejemplares similares